FOR HEALTHCARE PROFESSIONALS

AlnylamAct®

Genetic testing and counselling programs† for patients with hATTR offered at no charge‡



Inform your patients about this offer

† While the program is sponsored by Alnylam® Pharmaceuticals, all services are performed by independent third parties.
‡ To patients, healthcare professionals or payers.
hATTR=hereditary transthyretin-mediated amyloidosis

GENETIC TESTING

The importance of genetic testing

hATTR is a rare, rapidly progressive, life-threatening disease. It is caused by a mutation in the transthyretin (*TTR*) gene that results in misfolded TTR proteins. The disease can be difficult to recognize due to its variable clinical presentation and non-specific symptoms. Due to the rapid progression of the disease, it is important that patients with suspected hATTR undergo genetic testing in order to confirm a diagnosis as treatment for hATTR is most effective in the early stages of the disease.[1-3]

Ordering a genetic test

Request a PreventionGenetics specimen collection kit

from your Alnylam® Pharmaceuticals contact

OR

from the online ordering portal preventiongenetics.com/request-a-kit

PreventionGenetics offers the ability to send specimen collection kits to you or directly to your patients

If you have questions about your submission and/or the variant of uncertain significance (VUS) results, please contact the clinical support services at support@preventiongenetics.com or call 715-387-0484.

Genetic testing for hATTR can be ordered as an individual test.

Genetic testing can best confirm an hATTR diagnosis.

For questions about genetic testing and genetic counselling,

GENETIC COUNSELLING

AlnylamAct®

Inform your patients that genetic counselling support is available

Genetic counselling sessions help your patients:

- Understand a genetic test result
- Examine applicable next steps for the patient and their family
- Determine relatives for cascade testing

Inform patients that they can get genetic counselling at any time‡

- Refer your patients for genetic counselling when you order a genetic test
- You can select optional pre-test and/or post-test genetic counselling when filling out the test requisition form
- Genome Medical will contact the patient directly to schedule an appointment
- Patients may ask a genetic counsellor questions at anytime throughout the process, and an appointment may be scheduled through the patient portal once testing is completed

Prepare patients for the post-genetic counselling session

It is recommended that the patient set aside 30 minutes free from interruptions or distractions. The patient may consider asking family members about their family medical history ahead of the appointment. It is helpful for the genetic counsellor to understand if any family members have been diagnosed with medical conditions and at what age they were diagnosed.

Receive results

Genome Medical will email the patient a summary report, and patients may access the report through the online portal. The patient may then share the report results with you.

Encourage your patients to seek genetic counselling once a diagnosis is suspected or confirmed.

No charge **genetic testing** and **counselling services**

contact PreventionGenetics at preventiongenetics.com/contactus or 715-387-0484

‡ Refer to the Alnylam Act® hATTR requisition form for full details about eligibility criteria.

Patients aged 18 years or older with a suspected diagnosis or confirmed family history of hATTR may take part in the Alnylam Act® program. PreventionGenetics is the independent vendor providing this service.

How to order genetic testing online†

1. Sign up online

- Visit **preventiongenetics.com/sponsoredTesting** to set up an account
- Log in to order a test
- Specimen (blood, saliva or buccal) collection kits can be ordered online or requested from your Alnylam® Pharmaceuticals representative
  - Allow 2-3 days for delivery

2. Complete the PreventionGenetics requisition form for Alnylam Act® (hATTR amyloidosis) and symptom checklist

- Fax these to 715-406-4175 or insert in the PreventionGenetics Specimen collection kit before shipment

3. Submit patient sample

- Use a standard 4.0 mL lavender-top (ethylenediaminetetraacetic acid; EDTA) tube, saliva tube or buccal swab
- Submit the sample with completed forms
- Specimen and shipping requirements are available on the requisition form or online

4. Receive patient results

- A notification email will be sent to you when results are ready
  - Typically within 3 weeks
- If you created an online account, you can view the status of your order by logging into your account

† For assistance with account set-up, test ordering or alternative ways to order testing and submit samples, call PreventionGenetics at 715-387-0484.

The Alnylam Act® program was created to provide access to genetic testing and counselling to patients as a way to help Canadians make more informed decisions about their health. While Alnylam® Pharmaceuticals provides financial support for this program, tests and services are performed by independent third parties. Healthcare professionals must confirm that patients meet certain criteria to use the program. Alnylam® Pharmaceuticals receives de-identified patient data from this program, but at no time does Alnylam® Pharmaceuticals receive patient-identifiable information. Alnylam® Pharmaceuticals may use healthcare professional contact information for research purposes. Healthcare professionals or patients who use this program have no obligation to recommend, purchase, order, prescribe, promote, administer, use, or support any Alnylam® Pharmaceuticals product. No patients, healthcare professionals, or payers, including government payers, are billed for this program.

Alnylam® Pharmaceuticals is a biopharmaceutical company developing a potential new class of innovative medicines. We have a core focus on therapeutics toward genetically defined targets for the treatment of serious, life-threatening diseases with limited treatment options for patients and their caregivers.

To learn more about Alnylam® Pharmaceuticals, please visit www.alnylam.ca.

References: 1. Alcantara M, *et al*. Canadian guidelines for hereditary transthyretin amyloidosis polyneuropathy management. *Can J Neurol Sci* 2022;49:7-18. **2.** Conceição I, *et al*. "Red-flag" symptom clusters in transtheyretin familial amyloid polyneuropathy. *J Peripher Nerv Syst* 2016;21(1):5-9. **3.** Obici L, *et al*. Recommendations for presymptomatic genetic testing and management of individuals at risk for hereditary transthyretin amyloidosis. *Curr Opin Neurol* 2016;29(suppl 1):S27-S35.

Alnylam Canada ULC. 4 Robert Speck Parkway, Suite 1522 | Mississauga, Ontario L4Z 1S1
06, 2024
TTR-CAN-00057